Gene Therapy for Glioblastoma Multiforme

Area of Science:

• Neuro-oncology
• Molecular Biology
• Biotechnology

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain tumor with a <10% five-year survival rate.
• Current GBM treatments face challenges like poor drug delivery across the blood-brain barrier, drug resistance, and genetic complexity.
• Gene therapy presents a distinct mechanism to potentially overcome these limitations.

Purpose of the Study:

• To review current advancements in gene therapy for glioblastoma multiforme.
• To discuss various viral and nonviral vectors and their genetic payloads for GBM treatment.
• To explore the oncolytic and immunogenic effects of gene therapy agents in GBM.

Main Methods:

• Review of scientific literature on gene therapy applications in glioblastoma.
• Analysis of viral and nonviral vectors used for gene delivery.
• Examination of DNA transgenes and RNA inhibitors for anti-GBM therapy.

Main Results:

• Gene therapy utilizes diverse vectors and genetic cargoes to modify GBM cells.
• Oncolytic and immunogenic effects of gene therapy agents show promise for GBM treatment.
• Combination of gene therapy with standard treatments may enhance therapeutic outcomes.

Conclusions:

• Gene therapy represents a promising therapeutic avenue for glioblastoma multiforme.
• Further research into optimized vectors and genetic payloads is crucial.
• Investigating combination therapies could significantly improve GBM patient survival rates.